Protocol summary

Study aim
Determining and comparing the effect of Golqand herbal laxative and PEG Dribost syrup on children's performance
Design
A clinical trial with the control group, with parallel groups, single-blind, randomized, phase 2 on 96 patients. A randomized block was used for randomization.
Settings and conduct
The current study is a single-blind randomized clinical trial that is conducted in the medical centers of Fasa University of Medical Sciences. The research population includes children from 2 to 15 years old with constipation. 96 children are divided into groups in a blind manner. In case of any problem such as diarrhea, parents should inform the attending physician and they will be allowed to reduce the amount of PEG and Goleghand to ⅔ of the initial dose. If signs of fecal impaction are observed, additional laxatives such as paraffin will be administered at the rate of 1 to 3 cc/kg. Also, the form "satisfaction with the drug", Bristol consistency and side effects will be filled. At the end of the study (end of 8 weeks), all children are visited and forms are collected
Participants/Inclusion and exclusion criteria
Inclusion criteria 1. Children aged 2-15 years with constipation that has non-organic causes based on Rome IV criteria Exclusion criteria 1- Unwillingness to continue studying 2. Receiving treatment for constipation within 2 weeks before entering the study
Intervention groups
Group (group A): PEG 4000 in the form of syrup with a dose of 0.7 g/kg twice a day Group (group B): Goleghand Barij Majun with a dose of 0.5 g/kg once a day, in the morning fasting Group (group C): Goleghand Barij Majun with a dose of 0.5 g/kg three times a day Group (group D): control group of usual treatments
Main outcome variables
Examining stool shape using the Bristol scale to determine the effect of drugs, evaluating and comparing satisfaction with drugs, evaluating and comparing side effects of drugs

General information

Reason for update
Acronym
Fums
IRCT registration information
IRCT registration number: IRCT20240730062585N1
Registration date: 2024-08-16, 1403/05/26
Registration timing: prospective

Last update: 2024-08-16, 1403/05/26
Update count: 0
Registration date
2024-08-16, 1403/05/26
Registrant information
Name
Elham Kebriyaei
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 917 130 8290
Email address
e.kebriyaei@fums.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2024-08-22, 1403/06/01
Expected recruitment end date
2025-04-21, 1404/02/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Comparison of the Effect of Herbal Laxative (Goleghand) and PEG Syrup in Functional Constipation on children referred to medical centers of Fasa University of Medical Sciences( A single-blind randomized Controlled clinical trial study)
Public title
Comparison of the effect of herbal laxative drug Golgand and PEG syrup on children's performance: a randomized, single-blind clinical trial study
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Children aged 2-15 years with non-organic constipation according to Rome IV criteria Not having an allergy to medicinal plants Not taking laxatives 2 weeks ago Not having underlying digestive diseases No history of gastrointestinal surgery
Exclusion criteria:
Children diagnosed with IBS Receiving treatment for constipation within 2 weeks before entering the study Children with mental retardation or metabolic disease Children with Hirschirong or spinal anomaly or anorectal pathology Children who have undergone intestinal or stomach surgery The occurrence of sensitivity during the treatment period
Age
From 2 years old to 15 years old
Gender
Both
Phase
2
Groups that have been masked
  • Participant
Sample size
Target sample size: 96
Randomization (investigator's opinion)
Randomized
Randomization description
The required samples will be selected from the patients referred to the pediatric department of Hazrat Wali Asr Fasa Hospital using the available method. The samples will be assigned to three study groups using the random block method of 6. In this way, 12 blocks of 6 are made as follows. The sequence of blocks is written on a card. The sequences are then enveloped and placed in a container. The participant is asked to choose one of the envelopes. The order written on the card inside the envelope determines the status of 6 participants in the groups. Then the next person chooses a block. It should be noted that the selection of envelopes is done by placement And this action will be repeated 16 times.
Blinding (investigator's opinion)
Single blinded
Blinding description
This study will be done as one-way blinding, so that in this study, for blinding, the researcher will divide the groups with the names A (PEG) and B (Goleghand once a day), C (Goleghand twice a day) and D (control) and the patient will not know the type of medicine assigned to him.
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee of Fasa University of Medical Sciences
Street address
Ibn Sina Square, Fasa Medical Sciences
City
fasa
Province
Fars
Postal code
۷۴۶۱۶-۸۶۶۸۸
Approval date
2024-07-22, 1403/05/01
Ethics committee reference number
IR.FUMS.REC.1403.031

Health conditions studied

1

Description of health condition studied
constipation
ICD-10 code
K59.0
ICD-10 code description
constipation

Primary outcomes

1

Description
Constipation score in the evaluation of constipation
Timepoint
Before and after the intervention
Method of measurement
Bristol Stool Form Survey (BSFS)

2

Description
Constipation rate
Timepoint
8 weeks after the start of the intervention
Method of measurement
Bristol Stool Form Survey (BSFS)

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: Group (group A): PEG 4000 will be given in the form of syrup at a dose of 0.7 g/kg twice a day for 8 weeks. All explanations about how to use and side effects and delivery of the medicine to the child's parents by the pediatric assistant below the Pediatrician's opinion will be done. In case of any problem such as diarrhea, the parents should inform the attending physician and they will be allowed to reduce the amount of PEG and Goleghand to ⅔ of the initial dose. If fecal impaction symptoms are observed during the study period, additional laxatives such as paraffin will be administered at the rate of 1 to 3 cc/kg.
Category
Treatment - Drugs

2

Description
Intervention group: Group (group B): Goleghand Barij Majun (Golegand decoction of Bridge Essence Pharmaceutical Company, Kashan, Iran) with a dose of 0.5 g/kg once a day, in the morning fasting (with a maximum dose of one tablespoon equivalent to 5 g) for 8 weeks. will be. In case of any problem such as diarrhea, the parents should inform the attending physician and they will be allowed to reduce the amount of PEG and Goleghand to ⅔ of the initial dose. If fecal impaction symptoms are observed during the study period, additional laxatives such as paraffin will be administered at the rate of 1 to 3 cc/kg.
Category
Treatment - Drugs

3

Description
Intervention group: Group (group c): Goleghand Barij Majun (Goleghand potion of Brij Essan Pharmaceutical Company, Kashan, Iran) will be given at a dose of 0.5 g/kg three times a day for 8 weeks. In case of any problem such as diarrhea, the parents should inform the attending physician and they will be allowed to reduce the amount of PEG and Goleghand to ⅔ of the initial dose. If fecal impaction symptoms are observed during the study period, additional laxatives such as paraffin will be administered at the rate of 1 to 3 cc/kg.
Category
Treatment - Drugs

4

Description
Control group: In the control group, only routine procedures are performed
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Vali Asr Hospital
Full name of responsible person
Dorna Rahdar
Street address
Ibn Sina Square, Vali Asr Hospital
City
Fasa
Province
Fars
Postal code
۷۴۶۱۶-۸۶۶۸۸
Phone
+98 71 5331 4043
Email
valiasrfasa@fums.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Fasa University of Medical Sciences
Full name of responsible person
Dr Akbar Farjadfar
Street address
Ibn Sina Square, Fasa University of Medical Sciences
City
Fasa
Province
Fars
Postal code
۷۴۶۱۶-۸۶۶۸۸
Phone
+98 71 5331 6300
Email
research@fums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Fasa University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Fasa University of Medical Sciences
Full name of responsible person
Dorna Rahdar
Position
Pediatrics Resident
Latest degree
Medical doctor
Other areas of specialty/work
Pediatrics
Street address
Ibn Sina Square, Fasa University of Medical Sciences
City
Fasa
Province
Fars
Postal code
۷۴۶۱۶-۸۶۶۸۸
Phone
+98 71 5335 0994
Email
dr.rahdar54@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Fasa University of Medical Sciences
Full name of responsible person
Elham Kebriyaei
Position
Assistant Professor of Pediatrics
Latest degree
Specialist
Other areas of specialty/work
Pediatrics
Street address
Ibn Sina Square, Fasa University of Medical Sciences
City
Fasa
Province
Fars
Postal code
۷۴۶۱۶-۸۶۶۸۸
Phone
+98 71 5335 0994
Email
e.kebriyaei@fums.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
Fasa University of Medical Sciences
Full name of responsible person
Elham Kebriyaei
Position
Assistant Professor of Pediatrics
Latest degree
Specialist
Other areas of specialty/work
Pediatrics
Street address
Ibn Sina Square, Fasa University of Medical Sciences
City
Fasa
Province
Fars
Postal code
۷۴۶۱۶-۸۶۶۸۸
Phone
+98 71 5335 0994
Email
e.kebriyaei@fums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Not applicable
Data Dictionary
Not applicable
Title and more details about the data/document
After the end of the study, the analyzed data can be shared in the form of articles and thesis files.
When the data will become available and for how long
The access period starts 6 months after the results are published.
To whom data/document is available
All researchers working in universities of medical sciences.
Under which criteria data/document could be used
Data analysis based on statistical software
From where data/document is obtainable
Dr Elham Kebryaei
What processes are involved for a request to access data/document
Application submission, ethics committee approval, data submission
Comments
Loading...